HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Alembic Pharmaceuticals gets USFDA’s tentative nod for Larotrectinib Capsules
Jun-11-2026

Alembic Pharmaceuticals has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Larotrectinib Capsules, 25 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Vitrakvi Capsules, 25 mg and 100 mg, of Bayer Healthcare Pharmaceuticals Inc. (Bayer). 

Larotrectinib is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: a) have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, b) are metastatic or where surgical resection is likely to result in severe morbidity, and c) have no satisfactory alternative treatments or that have progressed following treatment.

Based on the most recent update to the USFDA’s online Paragraph IV database listings, the company is the sole first applicant to have filed its ANDA for Larotrectinib Capsules (25 mg and 100 mg), containing a Paragraph IV certification under the provisions of the Hatch-Waxman Act. Upon final approval of this ANDA by the USFDA, the company may be eligible for 180 days of generic marketing exclusivity in the U.S.

Larotrectinib Capsules, 25 mg and 100 mg, have an estimated market size of $91 million for twelve months ending March 2026 according to IQVIA. The company has a cumulative total of 241 ANDA approvals (221 final approvals and 20 tentative approvals) from USFDA.

Alembic Pharmaceuticals is involved in manufacturing and marketing of India Formulations, International Generics, and Active Pharmaceutical Ingredients with vertical integration capabilities.

  RELATED NEWS >>